SEC Filings TLDR

Fairmount Funds Management LLC has filed an amendment to its Schedule 13D, reporting an increased stake in Spyre Therapeutics, Inc. The filing indicates that Fairmount now holds 7,272,341 shares of common stock, representing an 8.99% ownership in the company. This marks a significant increase from previous filings, wit...

This filing is an amendment to the Schedule 13D for NovaBay Pharmaceuticals, Inc., filed by David E. Lazar. The amendment updates the ownership details and transactions involving the company's Series D and Series E Preferred Stock. Specifically, it details the sale of 441,325 shares of Series D Preferred Stock and the ...

NovaBay Pharmaceuticals, Inc. has filed an amendment to its Schedule 13D to disclose the termination of a voting agreement. The agreement, originally dated August 19, 2025, involved NovaBay Pharmaceuticals, Mr. David Elliot Lazar, and a group of stockholders including Jad Fakhry and entities associated with Poplar Poin...

This Amendment No. 2 to Schedule 13D, filed on July 8, 2025, updates the ownership details of common shares of Newegg Commerce, Inc. (NASDAQ: NEGG) by the Reporting Persons, including Fred Faching Chang, Tekhill USA LLC, and Nabal Spring, LLC. The amendment reflects changes in ownership due to a stock combination effec...

Amendment No. 4 to Schedule 13D for Ming Shing Group Holdings Ltd, filed on October 17, 2025, reports changes in the beneficial ownership of Ordinary Shares by Mr. Chi Ming Lam. Mr. Lam sold a total of 666,500 Ordinary Shares in a series of transactions between October 2, 2025, and October 15, 2025. This includes 66,50...

This Amendment No. 2 to Schedule 13D, filed by Cooperatieve Gilde Healthcare IV U.A., updates the initial filing from March 21, 2021, and Amendment No. 1 from October 14, 2025. The amendment reflects the sale of 2,298,711 common shares of LAVA Therapeutics N.V. by Gilde Healthcare between October 14, 2025, and October ...

This Schedule 13D/A amendment discloses Rubric Capital Management LP's updated 15.9% ownership stake in Heron Therapeutics following the automatic conversion of 94,610 preferred shares into 946,100 common shares after stockholder approval. The filing also details Rubric's $33.25 million purchase of convertible notes in...

Creative Realities, Inc. filed Amendment No. 2 to its Schedule 13D on October 17, 2025, disclosing changes related to its Common Stock. The amendment includes details about a Securities Purchase Agreement entered into on October 15, 2025, with certain accredited investors for a private placement of Series A Convertible...

This Amendment to Schedule 13D, filed by Huan Liu, the Chief Executive Officer, Director, and Chairman of the Board of Directors of Cheetah Net Supply Chain Service Inc., updates the beneficial ownership of the company's Class A common stock. Huan Liu beneficially owns 515,625 shares of Class A common stock issuable up...

Casdin Capital, LLC, along with its affiliates, has filed an amendment to its Schedule 13D, reporting a reduction in its stake in BioLife Solutions, Inc. As of October 17, 2025, Casdin Capital and its related entities collectively own 5,957,165 shares, representing 12.4% of the outstanding shares. This marks a decrease...

On October 15, 2025, Daniel S. Farb and certain affiliates (collectively, the Farb Parties) entered into an agreement with ARTELO BIOSCIENCES, INC. (the Issuer). The agreement includes several key provisions: (1) The Farb Parties agreed to withdraw their nomination of director candidates for the Issuer's 2025 annual me...

Anthony Hsieh, the reporting person, has filed Amendment No. 21 to Schedule 13D regarding his beneficial ownership of Class A Common Stock of loanDepot, Inc. This amendment updates the initial statement filed on November 16, 2021, and subsequent amendments. The amendment includes details of the sale of 1,300,000 shares...

Reprogrammed Interchange LLC and Reid Hoffman filed Amendment No. 7 to Schedule 13D for Vor Biopharma Inc., reporting changes in their ownership of the company's common stock. The amendment details a series of open market transactions from October 10, 2025, through October 14, 2025, where Reprogrammed Interchange LLC s...

Umbrella Global Energy S.A. filed Amendment No. 2 to Schedule 13D, updating its ownership details in Turbo Energy, S.A. The amendment reflects that Umbrella Global Energy S.A. holds 48,626,955 ordinary shares of Turbo Energy, representing 88.27% of the outstanding shares. The shares are beneficially owned by Enrique Se...

On October 14, 2025, Austin Russell, the Reporting Person, submitted a non-binding proposal to the Board of Luminar Technologies, Inc. regarding a potential transaction where Russell AI Labs would acquire 100% of the outstanding shares of the Class A Common Stock of the Company. The Proposed Transaction includes the in...

On October 15, 2025, Keros Therapeutics, Inc. entered into a Stock Purchase Agreement with the Pontifax Parties, resulting in the repurchase of 4,787,331 shares of Common Stock at $17.75 per share, totaling $84,975,125.25. This transaction led to the Pontifax Parties no longer being beneficial owners of more than 5% of...

Fresenius Medical Care AG (FME AG) filed Amendment No. 5 to its Schedule 13D for Humacyte, Inc. This amendment updates the beneficial ownership of FME AG, which now holds 18,312,735 shares of Humacyte's common stock, representing approximately 9.9% of the outstanding shares. The decrease in percentage ownership from 11...

This Amendment No. 6 to Schedule 13D, filed by Eric Sprott and 2176423 Ontario Ltd., updates the percentage of shares beneficially owned by the reporting persons in Hycroft Mining Holding Corp. As of October 14, 2025, the reporting persons beneficially own 29,897,880 shares of Class A common stock, representing 34.92% ...

Amendment No. 8 to the Schedule 13D for GoodRx Holdings, Inc. was filed by Spectrum Equity VII, L.P. and related entities. The amendment reports that on October 14, 2025, Spectrum Equity VII distributed 8,881,362 shares of GoodRx's Class A Common Stock to its limited partners for no consideration. Following this distri...

This filing represents Amendment No. 4 to the Schedule 13D for Garrett Motion Inc., initially filed on May 10, 2021. The amendment updates the ownership details of the reporting persons, including Cyrus Capital Partners, L.P., Cyrus Capital Partners GP, LLC, Cyrus Capital Advisors, L.L.C., and Stephen C. Freidheim. The...

Fresenius Medical Care AG (FME AG) filed Amendment No. 5 to its Schedule 13D regarding its ownership of Humacyte, Inc. common stock. The amendment reflects a decrease in FME AG's beneficial ownership from 11.8% to 9.9%, solely due to an increase in the number of outstanding shares of Humacyte's common stock. FME AG did...

This Amendment No. 5 to Schedule 13D is filed by AI ETI LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik (collectively, the "Reporting Persons") in respect of common stock of Climb Bio, Inc. The amendment updates the Schedule 13D originally filed on August 23, 2021, and subseque...

This filing, Amendment No. 18 to Schedule 13D, pertains to the common stock of Cipher Mining Inc. The amendment updates the beneficial ownership details of the reporting persons, including Bitfury Top HoldCo B.V., Bitfury Holding B.V., Bitfury Group Ltd, V3 Holding Ltd, and Valerijs Vavilovs. As of October 16, 2025, th...

Starboard Value LP has filed an amended Schedule 13D/A with the SEC, disclosing an 8.6% ownership stake in BILL Holdings, Inc. (BILL). The filing includes details of a Cooperation Agreement between Starboard and BILL, which outlines changes to the composition of BILL's Board of Directors. As part of the agreement, Step...

Perceptive Advisors LLC and Perceptive Xontogeny entered into a Voting and Support Agreement with BioCryst Pharmaceuticals, Inc. on October 14, 2025. The agreement requires them to vote their shares of Astria Therapeutics, Inc. in favor of the merger with BioCryst and restricts the transfer of their shares until the me...